Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen (Nasdaq: VTGN) will present at the TD Cowen 44th Annual Health Care Conference, with CEO Shawn Singh giving a corporate overview on March 6, 2024. Investors can arrange one-on-one meetings through their Cowen representative.
02/28/2024 - 08:30 AM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Health Care Conference in Boston, Massachusetts , March 4 to 6, 2024.
TD Cowen 44th Annual Health Care Conference
Shawn Singh, Chief Executive Officer, will present a corporate overview on Wednesday, March 6, 2024 at 10:30 a.m. Eastern Time.
A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com . Investors interested in arranging a one-on-one meeting during the conference should contact their Cowen representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228708023/en/
Investors:
Mark A. McPartland
(650) 577-3606
markmcp@vistagen.com
Media:
Caren Scannell
(650) 577-3601
cscannell@vistagen.com
Source: Vistagen
When is Vistagen (VTGN) presenting at the TD Cowen 44th Annual Health Care Conference?
Vistagen will present on March 6, 2024.
Who will give the corporate overview at the conference?
CEO Shawn Singh will present the corporate overview.
How can investors arrange one-on-one meetings during the conference?
Investors can contact their Cowen representative to arrange one-on-one meetings.
Where can the webcast of the presentation be accessed?
The webcast can be accessed through the 'Events' page in the 'Investors' section of Vistagen's website at www.Vistagen.com.
VistaGen Therapeutics Inc
VTGN Rankings
#3612 Ranked by Stock Gains
VTGN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About VTGN
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.